An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Revance to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) announces participation in upcoming investor conferences with key executives presenting fireside chats. CEO Mark Foley and CFO Tobin Schilke to present at Cowen 44th Annual Healthcare Conference on March 5, 2024, and CEO Mark Foley at Barclays Global Healthcare Conference on March 12, 2024.
Positive
None.
Negative
None.
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences.
Cowen 44th Annual Healthcare Conference
Chief Executive Officer, Mark Foley and Chief Financial Officer, Tobin Schilke are scheduled to participate in a fireside chat on Tuesday, March 5, 2024, at 12:50p.m. EST, in Boston, Massachusetts.
Barclays Global Healthcare Conference 2024
Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, March 12, 2024, at 9:30a.m. EST, in Miami, Florida.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (daxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.
“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
